A guide for urogynecologic patient care utilizing telemedicine during the COVID-19 pandemic: review of existing evidence

Cara L Grimes, Ethan M Balk, Catrina C Crisp, Danielle D Antosh, Miles Murphy, Gabriela E Halder, Peter C Jeppson, Emily E Weber LeBrun, Sonali Raman, Shunaha Kim-Fine, Cheryl Iglesia, Alexis A Dieter, Ladin Yurteri-Kaplan, Gaelen Adam, Kate V Meriwether, Cara L Grimes, Ethan M Balk, Catrina C Crisp, Danielle D Antosh, Miles Murphy, Gabriela E Halder, Peter C Jeppson, Emily E Weber LeBrun, Sonali Raman, Shunaha Kim-Fine, Cheryl Iglesia, Alexis A Dieter, Ladin Yurteri-Kaplan, Gaelen Adam, Kate V Meriwether

Abstract

Introduction and hypothesis: The COVID-19 pandemic and the desire to "flatten the curve" of transmission have significantly affected the way providers care for patients. Female Pelvic Medicine and Reconstructive Surgeons (FPMRS) must provide high quality of care through remote access such as telemedicine. No clear guidelines exist on the use of telemedicine in FPMRS. Using expedited literature review methodology, we provide guidance regarding management of common outpatient urogynecology scenarios during the pandemic.

Methods: We grouped FPMRS conditions into those in which virtual management differs from direct in-person visits and conditions in which treatment would emphasize behavioral and conservative counseling but not deviate from current management paradigms. We conducted expedited literature review on four topics (telemedicine in FPMRS, pessary management, urinary tract infections, urinary retention) and addressed four other topics (urinary incontinence, prolapse, fecal incontinence, defecatory dysfunction) based on existing systematic reviews and guidelines. We further compiled expert consensus regarding management of FPMRS patients in the virtual setting, scenarios when in-person visits are necessary, symptoms that should alert providers, and specific considerations for FPMRS patients with suspected or confirmed COVID-19.

Results: Behavioral, medical, and conservative management will be valuable as first-line virtual treatments. Certain situations will require different treatments in the virtual setting while others will require an in-person visit despite the risks of COVID-19 transmission.

Conclusions: We have presented guidance for treating FPMRS conditions via telemedicine based on rapid literature review and expert consensus and presented it in a format that can be actively referenced.

Keywords: COVID-19; FPMRS; Pandemic; Systematic review; Telemedicine; Urogynecology; Virtual visit.

Conflict of interest statement

Grimes: Expert testimony for Johnson and Johnson.

Meriwether: Consultant for RBI medical, Travel reimbursements from SGS (voting board member as Research Chair), Book editing/authorship royalties from Elsevier.

Jeppson: Consultant for Johnson & Johnson.

Balk: Consultant for society for Gynecologic Surgeons and American Association of Gynecologic Laparoscopists.

Murphy: Expert witness for Johnson and Johnson, Boston Scientific, President of Soceity of Gynecologic Surgeons.

No conflicts: Balk, Crisp, Antosh, Adam, Weber LeBrun, Halder, Kim-Fine, Dieter, Raman, Yurteri-Kaplan, Iglesia.

Figures

Fig. 1
Fig. 1
Vaginal discharge meta-analysis
Fig. 2
Fig. 2
Vaginitis meta-analysis
Fig. 3
Fig. 3
Erosion meta-analysis
Fig. 4
Fig. 4
Urinary retention meta-analysis

References

    1. Smith AC, Thomas E, Snoswell CL, Haydon H, Mehrotra A, Clemensen J, Caffery LJ (2020) Telehealth for global emergencies: Implications for coronavirus disease 2019 (COVID-19). J Telemed Telecare 1357633X20916567. 10.1177/1357633X20916567.
    1. Rogers RG, Swift S. The world is upside down; how coronavirus changes the way we care for our patients. Int Urogynecol J. 2020. 10.1007/s00192-020-04292-7.
    1. Agency for Healthcare Research and Quality Evidence-based Practice Center Program Rapid Review Guidance Document. . Accessed 4 Apr 2020.
    1. Balzarro M, Rubilotta E, Trabacchin N, Mancini V, Costantini E, Artibani W, Antonelli A. A prospective comparative study of the feasibility and reliability of telephone follow-up in female urology: the patient Home Office novel evaluation (PHONE) study. Urology. 2020;136:82–87. doi: 10.1016/j.urology.2019.10.021.
    1. Barry HC, Hickner J, Ebell MH, Ettenhofer T. A randomized controlled trial of telephone management of suspected urinary tract infections in women. J Fam Pract. 2001;50:589–594.
    1. Gordon AS, Adamson WC, DeVries AR. Virtual visits for acute, nonurgent care: A claims analysis of episode-level utilization. J Med Internet Res. 2017;19:e35. doi: 10.2196/jmir.6783.
    1. Jones G, Brennan V, Jacques R, Wood H, Dixon S, Radley S. Evaluating the impact of a “virtual clinic” on patient experience, personal and provider costs of care in urinary incontinence: A randomised controlled trial. PLoS One. 2018;13:e0189174. doi: 10.1371/journal.pone.0189174.
    1. Mehrotra A, Paone S, Martich GD, Albert SM, Shevchik GJ. A comparison of care at e-visits and physician office visits for sinusitis and urinary tract infection. JAMA Intern Med. 2013;173:72–74. doi: 10.1001/2013.jamainternmed.305.
    1. Tates K, Antheunis ML, Kanters S, Nieboer TE, Gerritse MB. The effect of screen-to-screen versus face-to-face consultation on doctor-patient communication: an experimental study with simulated patients. J Med Internet Res. 2017;19:e421. doi: 10.2196/jmir.8033.
    1. Thompson JC, Cichowski SB, Rogers RG, Qeadan F, Zambrano J, Wenzl C, Jeppson PC, Dunivan GC, Komesu YM. Outpatient visits versus telephone interviews for postoperative care: a randomized controlled trial. Int Urogynecol J. 2019;30:1639–1646. doi: 10.1007/s00192-019-03895-z.
    1. Akbar N, Dobson EL, Keefer M, Munsiff S, Dumyati G. 1082. Hold the phone: antibiotic prescribing practices associated with nonvisit encounters for urinary tract infections (UTIs) in urology clinics. Open Forum Infect Dis. 2019;6:S384. doi: 10.1093/ofid/ofz360.946.
    1. Schlittenhardt M, Smith SC, Ward-Smith P. Tele-continence care: A novel approach for providers. Urol Nurs. 2016;36:217–223. doi: 10.7257/1053-816X.2016.36.5.217.
    1. International Urogynecologic Association (IUGA) Your Pelvic Floor Leaflets. . Accessed 5 Apr 2020.
    1. American Urogynecologic Association (AUGS) Voices for Pelvic Floor Disorders Fact Sheets and Downloads. . Accessed 5 Apr 2020.
    1. National Association for Continence (NAFC) Urinary incontinence Education Learning Library. . Accessed 5 Apr 2020.
    1. Centers for Medicare and Medicaid Services (CMS) Medicare Telemedicine Healthcare Provider Fact Sheet. . Accessed 3 Apr 2020.
    1. Miceli A, Fernández-Sánchez M, Polo-Padillo J, Dueñas-Díez J-L. Is it safe and effective to maintain the vaginal pessary without removing it for 2 consecutive years? Int Urogynecol J. 2020. 10.1007/s00192-020-04240-5.
    1. Propst K, Mellen C, O’Sullivan DM, Tulikangas PK. Timing of office-based pessary care: A randomized controlled trial. Obstet Gynecol. 2020;135:100–105. doi: 10.1097/AOG.0000000000003580.
    1. Tam M-S, Lee VYT, Yu ELM, Wan RSF, Tang JSM, He JMY, Lui LKY, Chiu K-P, Cheung RYK, Lee K-W. The effect of time interval of vaginal ring pessary replacement for pelvic organ prolapse on complications and patient satisfaction: A randomised controlled trial. Maturitas. 2019;128:29–35. doi: 10.1016/j.maturitas.2019.07.002.
    1. Cheung RYK, Lee JHS, Lee LL, Chung TKH, Chan SSC. Vaginal pessary in women with symptomatic pelvic organ prolapse: A randomized controlled trial. Obstet Gynecol. 2016;128:73–80. doi: 10.1097/AOG.0000000000001489.
    1. Thys SD, Hakvoort RA, Asseler J, Milani AL, Vollebregt A, Roovers JP. Effect of pessary cleaning and optimal time interval for follow-up: a prospective cohort study. Int Urogynecol J. 2020. 10.1007/s00192-019-04200-8.
    1. Chien C-W, Lo T-S, Tseng L-H, Lin Y-H, Hsieh W-C, Lee S-J. Long-term outcomes of self-management Gellhorn pessary for symptomatic pelvic organ prolapse. Female Pelvic Med Reconstr Surg. 2019. 10.1097/SPV.0000000000000770.
    1. Lone F, Thakar R, Sultan AH, Karamalis G. A 5-year prospective study of vaginal pessary use for pelvic organ prolapse. Int J Gynaecol Obstet. 2011;114:56–59. doi: 10.1016/j.ijgo.2011.02.006.
    1. Wu V, Farrell SA, Baskett TF, Flowerdew G. A simplified protocol for pessary management. Obstet Gynecol. 1997;90:990–994. doi: 10.1016/s0029-7844(97)00481-x.
    1. Coolen A-LWM, Troost S, Mol BWJ, Roovers J-PWR, Bongers MY. Primary treatment of pelvic organ prolapse: pessary use versus prolapse surgery. Int Urogynecol J. 2018;29:99–107. doi: 10.1007/s00192-017-3372-x.
    1. Yang J, Han J, Zhu F, Wang Y. Ring and Gellhorn pessaries used in patients with pelvic organ prolapse: a retrospective study of 8 years. Arch Gynecol Obstet. 2018;298:623–629. doi: 10.1007/s00404-018-4844-z.
    1. Ramsay S, Tu LM, Tannenbaum C. Natural history of pessary use in women aged 65 - 74 versus 75 years and older with pelvic organ prolapse: a 12-year study. Int Urogynecol J. 2016;27:1201–1207. doi: 10.1007/s00192-016-2970-3.
    1. Collins S, Beigi R, Mellen C, O’Sullivan D, Tulikangas P. The effect of pessaries on the vaginal microenvironment. Am J Obstet Gynecol. 2015;212:60.e1–60.e6. doi: 10.1016/j.ajog.2014.07.024.
    1. de A Coelho SC, Giraldo PC, Florentino JO, de Castro EB, LGO B, CRT J. Can the pessary use modify the vaginal microbiological flora? A cross-sectional study. Rev Bras Ginecol Obstet. 2017;39:169–174. doi: 10.1055/s-0037-1601437.
    1. Deng M, Ding J, Ai F, Zhu L. Clinical use of ring with support pessary for advanced pelvic organ prolapse and predictors of its short-term successful use. Menopause. 2017;24:954–958. doi: 10.1097/GME.0000000000000859.
    1. Manchana T. Ring pessary for all pelvic organ prolapse. Arch Gynecol Obstet. 2011;284:391–395. doi: 10.1007/s00404-010-1675-y.
    1. Dessie SG, Armstrong K, Modest AM, Hacker MR, Hota LS. Effect of vaginal estrogen on pessary use. Int Urogynecol J. 2016;27:1423–1429. doi: 10.1007/s00192-016-3000-1.
    1. Deng M, Ding J, Ai F, Zhu L. Successful use of the Gellhorn pessary as a second-line pessary in women with advanced pelvic organ prolapse. Menopause. 2017;24:1277–1281. doi: 10.1097/GME.0000000000000909.
    1. Sasaki T, Agari T, Date I. Devices and practices for improving the accuracy of deep brain stimulation. No Shinkei Geka. 2018;46:751–762. doi: 10.11477/mf.1436203809.
    1. Kasper S. Editorial issue 4/2019. Int J Psychiatry Clin Pract. 2019;23:237. doi: 10.1080/13651501.2019.1688484.
    1. Swedish Urinary Tract Infection Study Group Interpretation of the bacteriologic outcome of antibiotic treatment for uncomplicated cystitis: impact of the definition of significant bacteriuria in a comparison of ritipenem acoxil with norfloxacin. Swedish urinary tract infection study group. Clin Infect Dis. 1995;20:507–513. doi: 10.1093/clinids/20.3.507.
    1. Jansåker F, Frimodt-Møller N, Bjerrum L, Dahl Knudsen J. The efficacy of pivmecillinam: 3 days or 5 days t.i.d against community acquired uncomplicated lower urinary tract infections—a randomized, double-blinded, placebo-controlled clinical trial study protocol. BMC Infect Dis. 2016;16:727. doi: 10.1186/s12879-016-2022-0.
    1. García-Rodríguez JA. Bacteriological comparison of cefixime in patients with noncomplicated urinary tract infection in Spain. Preliminary Results Chemotherapy. 1998;44(Suppl 1):28–30. doi: 10.1159/000048461.
    1. Guneysel O, Onur O, Erdede M, Denizbasi A. Trimethoprim/sulfamethoxazole resistance in urinary tract infections. J Emerg Med. 2009;36:338–341. doi: 10.1016/j.jemermed.2007.08.068.
    1. Johnson JR, Stamm WE. Urinary tract infections in women: diagnosis and treatment. Ann Intern Med. 1989;111:906–917. doi: 10.7326/0003-4819-111-11-906.
    1. Johnson L, Sabel A, Burman WJ, Everhart RM, Rome M, MacKenzie TD, Rozwadowski J, Mehler PS, Price CS. Emergence of fluoroquinolone resistance in outpatient urinary Escherichia coli isolates. Am J Med. 2008;121:876–884. doi: 10.1016/j.amjmed.2008.04.039.
    1. Kahan NR, Kahan E, Waitman D-A, Chinitz DP. Economic evaluation of an updated guideline for the empiric treatment of uncomplicated urinary tract infection in women. Isr Med Assoc J. 2004;6:588–591.
    1. Leibovici L, Greenshtain S, Cohen O, Wysenbeek AJ. Toward improved empiric management of moderate to severe urinary tract infections. Arch Intern Med. 1992;152:2481–2486. doi: 10.1001/archinte.1992.00400240097016.
    1. Mishra B, Srivastava S, Singh K, Pandey A, Agarwal J. Symptom-based diagnosis of urinary tract infection in women: are we over-prescribing antibiotics? Int J Clin Pract. 2012;66:493–498. doi: 10.1111/j.1742-1241.2012.02906.x.
    1. Tchesnokova V, Riddell K, Scholes D, Johnson JR, Sokurenko EV. The uropathogenic Escherichia coli subclone sequence type 131-H30 is responsible for most antibiotic prescription errors at an urgent care clinic. Clin Infect Dis. 2019;68:781–787. doi: 10.1093/cid/ciy523.
    1. van der Donk CFM, van de Bovenkamp JHB, De Brauwer EIGB, De Mol P, Feldhoff K-H, Kalka-Moll WM, Nys S, Thoelen I, Trienekens TAM, Stobberingh EE. Antimicrobial resistance and spread of multi drug resistant Escherichia coli isolates collected from nine urology services in the Euregion Meuse-Rhine. PLoS One. 2012;7:e47707. doi: 10.1371/journal.pone.0047707.
    1. Linsenmeyer K, Strymish J, Gupta K. Two simple rules for improving the accuracy of empiric treatment of multidrug-resistant urinary tract infections. Antimicrob Agents Chemother. 2015;59:7593–7596. doi: 10.1128/AAC.01638-15.
    1. MacFadden DR, Ridgway JP, Robicsek A, Elligsen M, Daneman N. Predictive utility of prior positive urine cultures. Clin Infect Dis. 2014;59:1265–1271. doi: 10.1093/cid/ciu588.
    1. Bischoff S, Walter T, Gerigk M, Ebert M, Vogelmann R. Empiric antibiotic therapy in urinary tract infection in patients with risk factors for antibiotic resistance in a German emergency department. BMC Infect Dis. 2018;18:56. doi: 10.1186/s12879-018-2960-9.
    1. Bonfiglio G, Mattina R, Lanzafame A, Cammarata E, Tempera G, Italian Medici Medicina Generale (MMG) Group Fosfomycin tromethamine in uncomplicated urinary tract infections: a clinical study. Chemotherapy. 2005;51:162–166. doi: 10.1159/000085625.
    1. Chiu C-C, Lin T-C, Wu R-X, Yang Y-S, Hsiao P-J, Lee Y, Lin J-C, Chang F-Y. Etiologies of community-onset urinary tract infections requiring hospitalization and antimicrobial susceptibilities of causative microorganisms. J Microbiol Immunol Infect. 2017;50:879–885. doi: 10.1016/j.jmii.2016.08.008.
    1. Clark R, Welk B. The ability of prior urinary cultures results to predict future culture results in neurogenic bladder patients. Neurourol Urodyn. 2018;37:2645–2650. doi: 10.1002/nau.23713.
    1. Datta R, Advani S, Rink A, Bianco L, Van Ness PH, Quagliarello V, et al. Increased fluoroquinolone-susceptibility and preserved nitrofurantoin-susceptibility among Escherichia coli urine isolates from women long-term care residents: A brief report. Open Access J Gerontol Geriatr Med. 2018. 10.19080/OAJGGM.2018.04.555636.
    1. Dokter J, Tennyson LE, Nguyen L, Han E, Sirls LT. The clinical rate of antibiotic change following empiric treatment for suspected urinary tract infections. Int Urol Nephrol. 2020;52:431–436. doi: 10.1007/s11255-019-02327-7.
    1. Neuzillet Y, Naber KG, Schito G, Gualco L, Botto H. French results of the ARESC study: clinical aspects and epidemiology of antimicrobial resistance in female patients with cystitis. Implications for empiric therapy. Med Mal Infect. 2012;42:66–75. doi: 10.1016/j.medmal.2011.07.005.
    1. Barry HC, Ebell MH, Hickner J. Evaluation of suspected urinary tract infection in ambulatory women: a cost-utility analysis of office-based strategies. J Fam Pract. 1997;44:49–60.
    1. Bent S, Saint S. The optimal use of diagnostic testing in women with acute uncomplicated cystitis. Am J Med. 2002;113(Suppl 1A):20S–28S. doi: 10.1016/s0002-9343(02)01056-2.
    1. DeAlleaume L, Tweed EM, Bonacci R. Clinical inquiries. When are empiric antibiotics appropriate for urinary tract infection symptoms? J Fam Pract. 2006;55(338):341–342.
    1. Ross AM. UTI antimicrobial resistance: tricky decisions ahead? Br J Gen Pract. 2000;50:612–613.
    1. Dixon T. Urinary tract infections. Management mayhem? Can Fam Physician. 1993;39:474–479.
    1. Giesen LGM, Cousins G, Dimitrov BD, van de Laar FA, Fahey T. Predicting acute uncomplicated urinary tract infection in women: a systematic review of the diagnostic accuracy of symptoms and signs. BMC Fam Pract. 2010;11:78. doi: 10.1186/1471-2296-11-78.
    1. Vellinga A, Cormican M, Hanahoe B, Murphy AW. Predictive value of antimicrobial susceptibility from previous urinary tract infection in the treatment of re-infection. Br J Gen Pract. 2010;60:511–513. doi: 10.3399/bjgp10X514765.
    1. McGregor JC, Elman MR, Bearden DT, Smith DH. Sex- and age-specific trends in antibiotic resistance patterns of Escherichia coli urinary isolates from outpatients. BMC Fam Pract. 2013;14:25. doi: 10.1186/1471-2296-14-25.
    1. George CE, Norman G, Ramana GV, Mukherjee D, Rao T. Treatment of uncomplicated symptomatic urinary tract infections: resistance patterns and misuse of antibiotics. J Family Med Prim Care. 2015;4:416–421. doi: 10.4103/2249-4863.161342.
    1. Anger J, Lee U, Ackerman AL, Chou R, Chughtai B, Clemens JQ, Hickling D, Kapoor A, Kenton KS, Kaufman MR, Rondanina MA, Stapleton A, Stothers L, Chai TC. Recurrent uncomplicated urinary tract infections in women: AUA/CUA/SUFU guideline. J Urol. 2019;202:282–289. doi: 10.1097/JU.0000000000000296.
    1. Hanlon JT, Perera S, Drinka PJ, Crnich CJ, Schweon SJ, Klein-Fedyshin M, Wessel CB, Saracco S, Anderson G, Mulligan M, Nace DA. The IOU consensus recommendations for empirical therapy of cystitis in nursing home residents. J Am Geriatr Soc. 2019;67:539–545. doi: 10.1111/jgs.15726.
    1. Andriole VT. When to do culture in urinary tract infections. Int J Antimicrob Agents. 1999;11:253–255. doi: 10.1016/s0924-8579(99)00025-4.
    1. Le TP, Miller LG. Empirical therapy for uncomplicated urinary tract infections in an era of increasing antimicrobial resistance: a decision and cost analysis. Clin Infect Dis. 2001;33:615–621. doi: 10.1086/322603.
    1. Bader MS, Hawboldt J, Brooks A. Management of complicated urinary tract infections in the era of antimicrobial resistance. Postgrad Med. 2010;122:7–15. doi: 10.3810/pgm.2010.11.2217.
    1. Hsueh P-R, Hoban DJ, Carmeli Y, Chen S-Y, Desikan S, Alejandria M, Ko W-C, Binh TQ. Consensus review of the epidemiology and appropriate antimicrobial therapy of complicated urinary tract infections in Asia-Pacific region. J Inf Secur. 2011;63:114–123. doi: 10.1016/j.jinf.2011.05.015.
    1. McCue JD. Rationale for the use of oral fluoroquinolones as empiric treatment of nursing home infections. Arch Fam Med. 1994;3:157–164. doi: 10.1001/archfami.3.2.157.
    1. Lutters M, Vogt-Ferrier NB (2008) Antibiotic duration for treating uncomplicated, symptomatic lower urinary tract infections in elderly women. Cochrane Database Syst Rev CD001535. 10.1002/14651858.CD001535.pub2.
    1. Stapleton A. Urinary tract infections in patients with diabetes. Am J Med. 2002;113(Suppl 1A):80S–84S. doi: 10.1016/s0002-9343(02)01062-8.
    1. Wojno KJ, Baunoch D, Luke N, Opel M, Korman H, Kelly C, Jafri SMA, Keating P, Hazelton D, Hindu S, Makhloouf B, Wenzler D, Sabry M, Burks F, Penaranda M, Smith DE, Korman A, Sirls L. Multiplex PCR based urinary tract infection (UTI) analysis compared to traditional urine culture in identifying significant pathogens in symptomatic patients. Urology. 2020;136:119–126. doi: 10.1016/j.urology.2019.10.018.
    1. Kranjčec B, Papeš D, Altarac S. D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial. World J Urol. 2014;32:79–84. doi: 10.1007/s00345-013-1091-6.
    1. McQuiston Haslund J, Rosborg Dinesen M, Sternhagen Nielsen AB, Llor C, Bjerrum L. Different recommendations for empiric first-choice antibiotic treatment of uncomplicated urinary tract infections in Europe. Scand J Prim Health Care. 2013;31:235–240. doi: 10.3109/02813432.2013.844410.
    1. Naber KG, Wullt B, Wagenlehner FME. Antibiotic treatment of uncomplicated urinary tract infection in premenopausal women. Int J Antimicrob Agents. 2011;38(Suppl):21–35. doi: 10.1016/j.ijantimicag.2011.09.003.
    1. Knottnerus BJ, Grigoryan L, Geerlings SE, Moll van Charante EP, Verheij TJM, Kessels AGH, ter Riet G. Comparative effectiveness of antibiotics for uncomplicated urinary tract infections: network meta-analysis of randomized trials. Fam Pract. 2012;29:659–670. doi: 10.1093/fampra/cms029.
    1. Gupta K. Addressing antibiotic resistance. Dis Mon. 2003;49:99–110. doi: 10.1067/mda.2003.10.
    1. Nicolle L, Anderson PAM, Conly J, Mainprize TC, Meuser J, Nickel JC, Senikas VM, Zhanel GG. Uncomplicated urinary tract infection in women. Current practice and the effect of antibiotic resistance on empiric treatment. Can Fam Physician. 2006;52:612–618.
    1. Cohn EB, Schaeffer AJ. Urinary tract infections in adults. ScientificWorldJournal. 2004;4(Suppl 1):76–88. doi: 10.1100/tsw.2004.50.
    1. File TM, Tan JS. Urinary tract infections in the elderly. Geriatrics. 1989;44(Suppl A):15–19.
    1. Das R, Perrelli E, Towle V, Van Ness PH, Juthani-Mehta M. Antimicrobial susceptibility of bacteria isolated from urine samples obtained from nursing home residents. Infect Control Hosp Epidemiol. 2009;30:1116–1119. doi: 10.1086/647981.
    1. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, Moran GJ, Nicolle LE, Raz R, Schaeffer AJ, Soper DE, Infectious Diseases Society of America, European Society for Microbiology and Infectious Diseases International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52:e103–e120. doi: 10.1093/cid/ciq257.
    1. Bradley MS, Beigi RH, Shepherd JP. A cost-minimization analysis of treatment options for postmenopausal women with dysuria. Am J Obstet Gynecol. 2019;221:505.e1–505.e7. doi: 10.1016/j.ajog.2019.04.031.
    1. Rothberg MB, Wong JB. All dysuria is local. A cost-effectiveness model for designing site-specific management algorithms. J Gen Intern Med. 2004;19:433–443. doi: 10.1111/j.1525-1497.2004.10440.x.
    1. Fenwick EA, Briggs AH, Hawke CI. Management of urinary tract infection in general practice: a cost-effectiveness analysis. Br J Gen Pract. 2000;50:635–639.
    1. McKinnell JA, Stollenwerk NS, Jung CW, Miller LG. Nitrofurantoin compares favorably to recommended agents as empirical treatment of uncomplicated urinary tract infections in a decision and cost analysis. Mayo Clin Proc. 2011;86:480–488. doi: 10.4065/mcp.2010.0800.
    1. Concia E, Bragantini D, Mazzaferri F. Clinical evaluation of guidelines and therapeutic approaches in multi drug-resistant urinary tract infections. J Chemother. 2017;29:19–28. doi: 10.1080/1120009X.2017.1380397.
    1. Faro S, Fenner DE. Urinary tract infections. Clin Obstet Gynecol. 1998;41:744–754. doi: 10.1097/00003081-199809000-00030.
    1. Nicolle LE. Update in adult urinary tract infection. Curr Infect Dis Rep. 2011;13:552–560. doi: 10.1007/s11908-011-0212-x.
    1. Naber KG. Which fluoroquinolones are suitable for the treatment of urinary tract infections? Int J Antimicrob Agents. 2001;17:331–341. doi: 10.1016/S0924-8579(00)00362-9.
    1. Buckley BS, Lapitan MCM (2010) Drugs for treatment of urinary retention after surgery in adults. Cochrane Database Syst Rev CD008023. 10.1002/14651858.CD008023.pub2.
    1. Burgio KL. Behavioral treatment of urinary incontinence, voiding dysfunction, and overactive bladder. Obstet Gynecol Clin N Am. 2009;36:475–491. doi: 10.1016/j.ogc.2009.08.005.
    1. Dörflinger A, Monga A. Voiding dysfunction. Curr Opin Obstet Gynecol. 2001;13:507–512. doi: 10.1097/00001703-200110000-00010.
    1. Lavelle ES, Alam P, Meister M, Florian-Rodriguez M, Elmer-Lyon C, Kowalski J, Carter-Brooks C, Mazloomdost D, Zyczynski H, Lowder J, Gutman R, Sutkin G. Antibiotic prophylaxis during catheter-managed postoperative urinary retention after pelvic reconstructive surgery: A randomized controlled trial. Obstet Gynecol. 2019;134:727–735. doi: 10.1097/AOG.0000000000003462.
    1. Lusardi G, Lipp A, Shaw C (2013) Antibiotic prophylaxis for short-term catheter bladder drainage in adults. Cochrane Database Syst Rev CD005428. 10.1002/14651858.CD005428.pub2.
    1. Newman DK, Willson MM. Review of intermittent catheterization and current best practices. Urol Nurs. 2011;31(12–28):48.
    1. Ramsey S, Palmer M. The management of female urinary retention. Int Urol Nephrol. 2006;38:533–535. doi: 10.1007/s11255-005-5790-9.
    1. Shokrpour M, Shakiba E, Sirous A, Kamali A. Evaluation the efficacy of prophylactic tamsulosin in preventing acute urinary retention and other obstructive urinary symptoms following colporrhaphy surgery. J Family Med Prim Care. 2019;8:722–727. doi: 10.4103/jfmpc.jfmpc_18_19.
    1. Sutkin G, Lowder JL, Smith KJ. Prophylactic antibiotics to prevent urinary tract infection during clean intermittent self-catheterization (CISC) for management of voiding dysfunction after prolapse and incontinence surgery: a decision analysis. Int Urogynecol J Pelvic Floor Dysfunct. 2009;20:933–938. doi: 10.1007/s00192-009-0885-y.
    1. Tunitsky-Bitton E, Murphy A, Barber MD, Goldman HB, Vasavada S, Jelovsek JE. Assessment of voiding after sling: a randomized trial of 2 methods of postoperative catheter management after midurethral sling surgery for stress urinary incontinence in women. Am J Obstet Gynecol. 2015;212:597.e1–597.e9. doi: 10.1016/j.ajog.2014.11.033.
    1. Dieter AA, Wu JM, Gage JL, Feliciano KM, Willis-Gray MG. Catheter burden following urogynecologic surgery. Am J Obstet Gynecol. 2019;221:507.e1–507.e7. doi: 10.1016/j.ajog.2019.05.014.
    1. Hakvoort RA, Nieuwkerk PT, Burger MP, Emanuel MH, Roovers JP. Patient preferences for clean intermittent catheterisation and transurethral indwelling catheterisation for treatment of abnormal post-void residual bladder volume after vaginal prolapse surgery. BJOG. 2011;118:1324–1328. doi: 10.1111/j.1471-0528.2011.03056.x.
    1. Hentzen C, Haddad R, Ismael SS, Peyronnet B, Gamé X, Denys P, Robain G, Amarenco G, GRAPPPA (Clinical research Group of perineal dysfunctions in older adults) Intermittent self-catheterization in older adults: predictors of success for technique learning. Int Neurourol J. 2018;22:65–71. doi: 10.5213/inj.1835008.504.
    1. Hentzen C, Haddad R, Ismael SS, Peyronnet B, Gamé X, Denys P, Robain G, Amarenco G, Manceau P. Predictive factors of adherence to urinary self-catheterization in older adults. Neurourol Urodyn. 2019;38:770–778. doi: 10.1002/nau.23915.
    1. Kessler TM, Ryu G, Burkhard FC. Clean intermittent self-catheterization: a burden for the patient? Neurourol Urodyn. 2009;28:18–21. doi: 10.1002/nau.20610.
    1. Meekins AR, Siddiqui NY, Amundsen CL, Kuchibhatla M, Dieter AA. Improving postoperative efficiency: an algorithm for expedited void trials after urogynecologic surgery. South Med J. 2017;110:785–790. doi: 10.14423/SMJ.0000000000000733.
    1. Mulder FEM, Hakvoort RA, de Bruin JP, van der Post JAM, Roovers J-PWR. Comparison of clean intermittent and transurethral indwelling catheterization for the treatment of overt urinary retention after vaginal delivery: a multicentre randomized controlled clinical trial. Int Urogynecol J. 2018;29:1281–1287. doi: 10.1007/s00192-017-3452-y.
    1. Sassani JC, Stork A, Ruppert K, Bradley MS. Variables associated with an inability to learn clean intermittent self-catheterization after urogynecologic surgery. Int Urogynecol J. 2019. 10.1007/s00192-019-03974-1.
    1. Stoffel JT, Peterson AC, Sandhu JS, Suskind AM, Wei JT, Lightner DJ. AUA white paper on nonneurogenic chronic urinary retention: consensus definition, treatment algorithm, and outcome end points. J Urol. 2017;198:153–160. doi: 10.1016/j.juro.2017.01.075.
    1. Willis-Gray MG, Wu JM, Field C, Pulliam S, Husk KE, Brueseke TJ, et al. Is a postvoid residual necessary? A randomized trial of two postoperative voiding protocols. Female Pelvic Med Reconstr Surg. 2019. 10.1097/SPV.0000000000000743.
    1. Alas A, Hidalgo R, Espaillat L, Devakumar H, Davila GW, Hurtado E. Does spinal anesthesia lead to postoperative urinary retention in same-day urogynecology surgery? A retrospective review. Int Urogynecol J. 2019;30:1283–1289. doi: 10.1007/s00192-019-03893-1.
    1. Shatkin-Margolis A, Yook E, Hill AM, Crisp CC, Yeung J, Kleeman S, Pauls RN. Self-removal of a urinary catheter after Urogynecologic surgery: A randomized controlled trial. Obstet Gynecol. 2019;134:1027–1036. doi: 10.1097/AOG.0000000000003531.
    1. Hooton TM, Bradley SF, Cardenas DD, Colgan R, Geerlings SE, Rice JC, Saint S, Schaeffer AJ, Tambayh PA, Tenke P, Nicolle LE, Infectious Diseases Society of America Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 international clinical practice guidelines from the Infectious Diseases Society of America. Clin Infect Dis. 2010;50:625–663. doi: 10.1086/650482.
    1. Madersbacher H, Cardozo L, Chapple C, Abrams P, Toozs-Hobson P, Young JS, Wyndaele J-J, De Wachter S, Campeau L, Gajewski JB. What are the causes and consequences of bladder overdistension? ICI-RS 2011. Neurourol Urodyn. 2012;31:317–321. doi: 10.1002/nau.22224.
    1. Society of Gynecologic Surgeons A Guide to Female Clean Intermitent Self Catheterization. . Accessed 4 Apr 2020.
    1. Balk EM, Rofeberg VN, Adam GP, Kimmel HJ, Trikalinos TA, Jeppson PC. Pharmacologic and nonpharmacologic treatments for urinary incontinence in women: A systematic review and network meta-analysis of clinical outcomes. Ann Intern Med. 2019;170:465–479. doi: 10.7326/M18-3227.
    1. Simpson AN, Garbens A, Dossa F, Coyte PC, Baxter NN, McDermott CD. A cost-utility analysis of nonsurgical treatments for stress urinary incontinence in women. Female Pelvic Med Reconstr Surg. 2019;25:49–55. doi: 10.1097/SPV.0000000000000502.
    1. Richardson K, Fox C, Maidment I, Steel N, Loke YK, Arthur A, Myint PK, Grossi CM, Mattishent K, Bennett K, Campbell NL, Boustani M, Robinson L, Brayne C, Matthews FE, Savva GM. Anticholinergic drugs and risk of dementia: case-control study. BMJ. 2018;361:k1315. doi: 10.1136/bmj.k1315.
    1. Kelleher C, Hakimi Z, Zur R, Siddiqui E, Maman K, Aballéa S, Nazir J, Chapple C. Efficacy and tolerability of Mirabegron compared with Antimuscarinic monotherapy or combination therapies for overactive bladder: A systematic review and network meta-analysis. Eur Urol. 2018;74:324–333. doi: 10.1016/j.eururo.2018.03.020.
    1. Chen H-L, Chen T-C, Chang H-M, Juan Y-S, Huang W-H, Pan H-F, Chang Y-C, Wu C-M, Wang Y-L, Lee HY. Mirabegron is alternative to antimuscarinic agents for overactive bladder without higher risk in hypertension: a systematic review and meta-analysis. World J Urol. 2018;36:1285–1297. doi: 10.1007/s00345-018-2268-9.
    1. Barnes KL, Dunivan G, Jaramillo-Huff A, Krantz T, Thompson J, Jeppson P. Evaluation of smartphone pelvic floor exercise applications using standardized scoring system. Female Pelvic Med Reconstr Surg. 2019;25:328–335. doi: 10.1097/SPV.0000000000000563.
    1. Nekkanti S, Wu JM, Hudson CO, Pandya LK, Dieter AA. A randomized trial comparing continence pessary to a disposable intravaginal device [poise impressa®] for the non-surgical management of stress urinary incontinence. Female Pelvic Med Reconstr Surg. 2019;26:S95–S96.
    1. Balk E, Adam GP, Kimmel H, Rofeberg V, Saeed I, Jeppson P, Trikalinos T (2018) Nonsurgical treatments for urinary incontinence in women: A systematic review update. Agency for Healthcare Research and Quality (US), Rockville (MD).
    1. Wald A, Bharucha AE, Cosman BC, Whitehead WE. ACG clinical guideline: management of benign anorectal disorders. Am J Gastroenterol. 2014;109:1141–1157. doi: 10.1038/ajg.2014.190.
    1. Paquette IM, Varma MG, Kaiser AM, Steele SR, Rafferty JF. The american society of colon and rectal surgeons’ clinical practice guideline for the treatment of fecal incontinence. Dis Colon Rectum. 2015;58:623–636. doi: 10.1097/DCR.0000000000000397.
    1. Ridgeway BM, Weinstein MM, Tunitsky-Bitton E. American Urogynecologic Society (AUGS) best-practice statement on evaluation of obstructed defecation. Female Pelvic Med Reconstr Surg. 2018;24:383–391. doi: 10.1097/SPV.0000000000000635.
    1. American Urogynecologic Society (AUGS) Guidelines and Statements Committee. Carberry CL, Tulikangas PK, Ridgeway BM, Collins SA, Adam RA. American Urogynecologic Society (AUGS) best practice statement: evaluation and counseling of patients with pelvic organ prolapse. Female Pelvic Med Reconstr Surg. 2017;23:281–287. doi: 10.1097/SPV.0000000000000424.
    1. Bradley CS, Zimmerman MB, Qi Y, Nygaard IE. Natural history of pelvic organ prolapse in postmenopausal women. Obstet Gynecol. 2007;109:848–854. doi: 10.1097/01.AOG.0000255977.91296.5d.
    1. Gilchrist AS, Campbell W, Steele H, Brazell H, Foote J, Swift S. Outcomes of observation as therapy for pelvic organ prolapse: a study in the natural history of pelvic organ prolapse. Neurourol Urodyn. 2013;32:383–386. doi: 10.1002/nau.22298.
    1. Dumoulin C, Hunter KF, Moore K, Bradley CS, Burgio KL, Hagen S, Imamura M, Thakar R, Williams K, Chambers T. Conservative management for female urinary incontinence and pelvic organ prolapse review 2013: summary of the 5th international consultation on incontinence. Neurourol Urodyn. 2016;35:15–20. doi: 10.1002/nau.22677.
    1. Braekken IH, Majida M, Engh ME, Bø K. Can pelvic floor muscle training reverse pelvic organ prolapse and reduce prolapse symptoms? An assessor-blinded, randomized, controlled trial. Am J Obstet Gynecol. 2010;203:170.e1–170.e7. doi: 10.1016/j.ajog.2010.02.037.
    1. Modi RM, Hinton A, Pinkhas D, Groce R, Meyer MM, Balasubramanian G, Levine E, Stanich PP. Implementation of a defecation posture modification device: impact on bowel movement patterns in healthy subjects. J Clin Gastroenterol. 2019;53:216–219. doi: 10.1097/MCG.0000000000001143.
    1. ACOOAGCOPB, Dunivan GC, Chen CCG, Rogers RG (2019) ACOG practice bulletin no. 210: fecal incontinence. Obstet Gynecol 133:e260–e273. 10.1097/AOG.0000000000003187.
    1. Forte ML, Andrade KE, Butler M, Lowry AC, Bliss DZ, Slavin JL, Kane RL (2016) Treatments for Fecal Incontinence. Agency for Healthcare Research and Quality.
    1. Deutekom M, Dobben A (2005) Plugs for containing faecal incontinence. Cochrane Database Syst Rev CD005086. 10.1002/14651858.CD005086.pub2.
    1. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–513. doi: 10.1016/S0140-6736(20)30211-7.
    1. American College of Surgeons COVID-19: Recommendations for Management of Elective Surgical Procedures. . Accessed 2 Apr 2020.
    1. Weber Lebrun EE, Moawad NS, Rosenberg EI, Morey TE, Davies L, Collins WO, et al. COVID-19 pandemic: staged Management of Surgical Services for gynecology and obstetrics. Am J Obstet Gynecol. 2020. 10.1016/j.ajog.2020.03.038.
    1. Society of American Gastrointestinal and Endoscopic Surgeons SAGES and EAES Recommendations Regarding Surgical Response to COVID-19 Crisis. . Accessed 2 Apr 2020.
    1. Chen X, Liu Y, Gong Y, Guo X, Zuo M, Li J, et al. Perioperative Management of Patients Infected with the novel coronavirus: recommendation from the joint task force of the Chinese Society of Anesthesiology and the Chinese Association of Anesthesiologists. Anesthesiology. 2020. 10.1097/ALN.0000000000003301.
    1. Bacheller CD, Bernstein JM. Urinary tract infections. Med Clin North Am. 1997;81:719–730. doi: 10.1016/s0025-7125(05)70542-3.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅